Preliminary findings from clinical trials investigating uproleselan (GM-1271) in combination with standard-of-care (SOC) venetoclax (Venclexta) and azacitidine (Vidaza) or MEC (mitoxantrone, etoposide, and cytarabine) chemotherapy in patients with acute myeloid leukemia (AML) continue to demonstrate the potential for improving responses, leading to minimal residual disease (MRD) negativity in this population, according to Bhavana “Tina” Bhatnagar, DO.